A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre-and post-chemotherapy

Genome Research

Volumn 27, Issue 6, 2017, Pages 902-912

  Noorani, Ayesha ^a   Bornschein, Jan ^a   Lynch, Andy G ^b   Secrier, Maria ^b   Achilleos, Achilleas ^b   Eldridge, Matthew ^b   Bower, Lawrence ^b   Weaver, Jamie M J ^a   Crawte, Jason ^a   Ong, Chin Ann ^a   Shannon, Nicholas ^a   MacRae, Shona ^a   Grehan, Nicola ^a   Nutzinger, Barbara ^a   O'Donovan, Maria ^a,c   Hardwick, Richard ^c   Tavaré, Simon ^b   Fitzgerald, Rebecca C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRINUCLEOTIDE; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOREDUPLICATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE DOSAGE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; WHOLE GENOME SEQUENCING; ADENOCARCINOMA; BIOLOGY; CELL TRANSFORMATION; COPY NUMBER VARIATION; ESOPHAGUS; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; METABOLISM; MIDDLE AGED; MUTATION RATE; NEOADJUVANT THERAPY; PATHOLOGY; POINT MUTATION; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION RATE; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 85020292652     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.214296.116     Document Type: Article

References (31)

1. The 1000 Genomes Project Consortium. 2015. Aglobal reference for human genetic variation. Nature 526: 68-74.
2. Alderson D, Langley RE, Nankivell MG, Blazeby JM, Griffin M, Crellin A, Grabsch HI, Okines AFC, Goldstein C, Falk S, et al. 2015. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcino-ma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol 33: abstract 4002.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-421.
4. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Soceity of Gastroenterologyand the British Association ofSurgical Oncology. 2011.Guidelines for the management of oesophageal and gastric cancer. Gut 60: 1449-1472.
5. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Munoz M, Russnes HG, Helland A, et al. 2014. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 6: 514-527.
6. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. 2006. Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med 355: 11-20.
7. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45: 478-486.
8. Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, Kovac M, Ulahannan D, Palles C, Gillies RS, et al. 2016. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun 7: 11111.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
10. Klambauer G, Schwarzbauer K, Mayr A, Clevert DA, Mitterecker A, Bodenhofer U, Hochreiter S. 2012. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res 40: e69.
11. Lepage C, Drouillard A, Jouve JL, Faivre J. 2013. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis 45: 625-629.
12. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
13. Lynch A.2015. Crambled: aShiny application to enable intuitive resolution of conflicting cellularity estimates. F1000Res 4: 1407.
14. Lynch MJ, Mulvaney MJ, Hodges SC, Thompson TL, Thomason WE. 2016. Decomposition, nitrogen and carbon mineralization from food and cover crop residues in the central plateau of Haiti. Springerplus 5: 973.
15. Masclee GM, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC. 2014. The incidence of Barrett's oesophagus and oesophageal adenocarcino-ma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther 39: 1321-1330.
16. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303.
17. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. 2016. The Ensembl Variant Effect Predictor. Genome Biol 17: 122.
18. Medical Research Council Oesophageal Cancer Working Group. 2002. Surgical resection with or without preoperative chemotherapy in oeso-phageal cancer: a randomised controlled trial. Lancet 359: 1727-1733.
19. Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB, Marshall J, Raine K, Maddison M, Anderson E, Stratton MR, et al. 2014. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res 24: 1624-1636.
20. Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, McGranahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S, et al. 2015. Tracking the genomic evolution of esophageal adenocarcinoma through neoad-juvant chemotherapy. Cancer Discov 5: 821-831.
21. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, et al. 2012. The life history of 21 breast cancers. Cell 149: 994-1007.
22. Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, Holmes O, Fink JL, Quinn MC, Tang YH, et al. 2014. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun 5: 5224.
23. Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, et al. 2014. Effect of pre-operative chemoradiotherapy on outcome of patients with locally ad-vanced esophagogastric junction adenocarcinoma-a pilot study. Current Oncol 21: 125-133.
24. Rebucci M, Michiels C. 2013. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85: 1219-1226.
25. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. 2012. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28: 1811-1817.
26. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials Group. 2011. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12: 681-692.
27. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, et al. 2010. Allele-spe-cific copy number analysis of tumors. Proc Natl Acad Sci 107: 16910-16915.
28. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ, et al. 2014. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46: 837-843.
29. Woods D, Turchi JJ. 2013. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther 14: 379-389.
30. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, et al. 2015. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21: 751-759.
31. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, Cummins C, Clapham P, Fitzgerald S, Gil L, et al. 2016. Ensembl 2016. Nucleic Acids Res 44: D710-D716.